INTRODUCTION
Haemostasis is a physiological response to vascular injury and starts when blood is exposed to the subendothelial structures or connective tissue. One of the major haemostatic responses is blood coagulation, which is a cascade of reactions in which inactive precursor proteins are converted into active enzymes [1, 2] . Before the precursors can be activated, they first have to bind via Ca2+ to negatively charged phospholipids present at the site of injury [1, 2] . The phospholipids required to support the coagulation cascade in vivo are provided by activated platelets and endothelial cells but also by microvesicles shed from endothelial cells [3] and stimulated blood cells [4] [5] [6] .
The main trigger of the coagulation pathway is tissue factor which forms a complex with factor VII(a). This complex is able to activate the zymogen factors X and IX. Factor IXa forms a complex with factor VIII(a) which is then able to activate factor X [1, 2] . Factor Xa together with factor Va, phospholipids and Ca2+ forms the prothrombinase complex, which converts prothrombin into thrombin [1, 2] . Thrombin plays a pivotal role in blood coagulation because (a) it can activate fibrinogen which leads to fibrin formation, (b) it activates platelets, (c) it stabilizes fibrin via activation of factor XIII, (d) it is capable of accelerating its own formation via activation of factors V and VIII, (e) it activates the anticoagulant protein, protein C, and (f) it activates factor XI [1, 2, [7] [8] [9] .
Recently, a protein has been identified, purified and cloned which is capable of regulating the availability of negatively charged phospholipids for coagulation processes [10] [11] [12] . This protein, called annexin V, belongs to a large family of Ca2+-dependent phospholipid-binding proteins consisting of at least 13 different members [13] [14] [15] [16] . Most annexin molecules are built up of four homologous repeats (except for annexin VI which has PMA or TNF-a. rANV inhibited HUVEC-mediated factor Xa formation via the extrinsic as well as the intrinsic route. Activation of factor X by the tissue factor-factor VII-factor X complex and tenase complex was inhibited with IC50 values of 43 + 30 nM and 33 + 24 nM respectively. Endothelial-cellmediated generation ofthrombin by the prothrombinase complex was inhibited by rANV with an IC50 of 16 + 12 nM. Preincubation of rANV with the endothelial cells did not significantly influence the IC50 values. These results show that rANV binds to the same extent to quiescent, PMA-and TNF-stimulated HUVEC, and, as a result of this binding, rANV efficiently inhibits endothelialcell-mediated thrombin formation.
eight of those repeats) and a highly variable N-terminal tail (for reviews see refs [17, 18] ). Annexin V is present as an intracellular protein in endothelial cells [19] ; its concentration in plasma of healthy volunteers is less than 5 ng/ml [19] . Annexin V inhibits the coagulation cascade in vitro by binding the phospholipids required to support the formation of coagulation complexes [10, 11, [20] [21] [22] . In spite of its actions in vitro, the physiological function of annexin V in vivo remains to be clarified. However, its mechanism of anticoagulation predicts that it acts locally at sites of injury and makes it a candidate for a new type of antithrombotic therapy.
To investigate whether annexin V could serve as an antithrombotic drug, we have investigated the potential of recombinant annex V (rANV) to inhibit the coagulation cascade on a more physiological surface, namely the cell surface of cultured human umbilical-vein endothelial cells (HUVEC). Ravanat et al. [23] have studied the influence ofannexin V on the tissue factor-factor VII-dependent factor X activation of phorbol 12-myristate 13 
were obtained from Kabivitrum (Stockholm, Sweden). All other reagents were of the highest grade commercially available.
Coagulation proteins
All coagulation proteins used in this study were purified from human plasma. Prothrombin was purified as previously described by Fujikawa et al. [24] . Analysis in an SDS/PAGE system showed a single band at approximately 72 kDa under nonreducing conditions. The specific activity was 8 units/mg. aThrombin (3100 units/mg) was a generous gift from Dr. J. W. Fenton II (New York State Department of Health, Albany, NY, U.S.A.). Factor X was purified as described by Miletich et al. [25] and concentrated by chromatography on a Q-Sepharose column equilibrated in TBS buffer (150 mM NaCl, 50 mM Tris, pH 7.4). After the column had been washed with TBS, factor X was eluted with TBS buffer containing 25 mM CaCl2. Finally purified factor X was extensively dialysed against TBS buffer. SDS/PAGE analysis showed a single band at approx. 60 kDa under nonreducing conditions. The specific activity was 115 units/mg. Factor X was activated essentially as described by Bock et al. [26] , and, after purification, two bands of approx. 43 and 45 kDa were observed under non-reducing conditions.
Factor IX was purified as described by Mertens et al. [27] , and concentrated by diluting the pooled fractions in distilled water and subjecting them to Q-Sepharose chromatography. After the column had been washed with TBS, factor IX was eluted with TBS buffer containing 25 [27] . After activation, factor IXa was observed as a single band at approx. 44 kDa.
Factor VII was purified in the initial steps as described by Bajaj et al. [28] . However, after DEAE-Sepharose chromatography, the factor VII-containing fractions were pooled and diluted with 1 vol. of distilled water and subjected to chromatography on a Q-Sepharose column (1.5 cm x 15 cm). After the column had been washed with a buffer containing 17 mM Tris/HCl (pH 7.4), 50 mM NaCl and 1 mM benzamidin, factor VII was eluted with the same buffer containing 20 mM CaCl2.
The factor VII-containing fractions were pooled and extensively dialysed against TBS. Factor VII was observed as a single band on SDS/PAGE at approx. 48 kDa. The specific activity was 2100 units/mg.
Factor V was isolated with a monoclonal antibody against factor V (RU-FV3B1) which was coupled to Affigel-10 (2 mg/ml IgG). Citrate plasma (100 ml) was incubated with 50 ,ug/ml polybrene, 1 mM di-isopropyl fluorophosphate, 10 Factor VIII was obtained from Monoclate-P (Armour Pharmaceutical Company Ltd.) and dissolved according to the manufacturer's instructions to a concentration of 100 units/ml. Annexin V rANV was purified from Escherichia coli HBO1I transformed with plasmid pRH291 as described by Maurer-Fogy et al. [12] . It was radiolabelled with Na'251 (Amersham International, Amersham, Bucks., U.K.) to a specific radioactivity of approx. 450 ,uCi/mg using the lodogen procedure (Pierce Chemical Co.). Radiolabelled rANV was separated from free 1251 on a disposable PD-10 column (Pharmacia) equilibrated with TBS buffer. An autoradiograph of an SDS/PAGE showed a single radiolabelled band at approx. 36 kDa. The stock concentration used was approx. 14.5,uM.
Cell cultures HUVEC were isolated from umbilical veins and cultured as previously described by Jaffe et al. [29] with some minor modifications [30] . Endothelial cells of the second passage were subcultured on fibronectin (generous gift from Dr. J. A. van Figure 3 . Binding of radiolabelled rANV to quiescent HUVEC was saturable, and Scatchard analysis ( Figure  3 , inset) of the data revealed one class of binding site. An analysis of the results with a non-linear data-fitting program (Enzfitter) is shown in Table 1 .
The results in Table I were obtained with endothelial cells stimulated for 4.5 h. To investigate whether the dissociation constant or the number of binding sites varied with the period of stimulation, cells were stimulated with PMA and TNF for 0-30 h and binding studies were performed. As a control, tissue-factor and thrombomodulin activity on the endothelial cell surface were also measured. In time, tissue-factor expression is induced on the endothelial cell surface after stimulation with TNF or PMA (Figure 4a ). Also TNF induced down-regulation of thrombomodulin expression whereas PMA initially induced down-regulation of thrombomodulin but then induced up-regulation (Figure 4b ). The dissociation constants (Figure 4c ) and number of binding sites (Figure 4d ) for rANV binding to cultured HUVEC were not significantly changed.
Inhibition of endothellal-cell dependent procoagulant reactions by rANV Activation of the zymogens by the respective procoagulant complexes formed on endothelial cells was studied with purified coagulation factors. Coagulation factors were used at plasma concentrations, except for factor VII and factor VIII. Increasing the concentration of factor VII and factor VIII did not increase the rate of the reaction (results not shown). When indicated, HUVEC were stimulated with 300 pM TNF or 20 ng/ml PMA for 4.5 h to stimulate expression of tissue factor. All experiments were performed in the presence of 5 mM CaCl2 at 37 'C.
In this experimental setting, zymogen activation was observed for the TF/VII/X complex (Figure 5a ), the tenase complex ( Figure Sb) , the prothrombinase complex ( Figure Sc) and the TF/PTC complex ( Figure Sd) . In all cases, a lag time of between 20 and 25 min was observed. Inhibition of the different procoagulant complexes by rANV was investigated in experiments in which rANV was added simultaneously with the clotting factors to the endothelial cells ( Figure 5 ). rANV did not appear to influence the lag period which reflects the time required to assemble a functional complex on the HUVEC surface. However, the rate of zymogen activation was inhibited.
The ability of rANV to inhibit the different complexes was Figure 6 ) show that rANV is equally able to inhibit the activation of factor X, via the extrinsic and intrinsic route, prothrombin, via the prothrombinase complex, and the TF/PTC complex. All the complexes were inhibited by more than 95 % except the TF/VII/X complex in which tissue factor expression is induced with TNF, which was inhibited by 80%. If tissue factor expression was induced by PMA, the TF/VII/X complex was also inhibited by 80 % by rANV, but the IC50 value appeared to be 10 times higher (results not shown).
To investigate whether the type of stimulation of HUVEC monolayers influenced the activity of the prothrombinase complex, we compared the inhibition potency of rANV on TNF-and PMA-stimulated cells with that on quiescent unstimulated cells. There was no difference in thrombin formation on these three different phenotypes of HUVEC and the IC50 values for rANV were in the same range (results not shown). Table 2 summarizes the results of the inhibition experiments. The IC50 values vary from 16 to 43 nM but there is no significant difference between these for the different coagulation complexes. Furthermore, the IC50 values for preincubation and simultaneous incubation did not differ significantly.
DISCUSSION
A few years ago a new anticoagulant protein, annexin V, was isolated from endothelial cells [10] and placenta [11, 33] . It is a strong inhibitor in in vitro clotting tests [10,1 1] because of its high affinity for negatively charged phospholipids [20] [21] [22] . To investigate whether annexin V is also able to inhibit thrombin formation on more physiological surfaces such as endothelial cells, we have studied the binding of the recombinant protein to endothelial cells and correlated this binding with the protein's ability to inhibit endothelial-cell-mediated thrombin formation.
Here we show that rANV binds to cultured HUVEC with a Kd of about 16 nM and approx. 8.8 x 106 binding sites/cell. Stimulation of cultured HUVEC for different time periods with TNF or PMA did not change the binding characteristics, in spite of clearly observed changes in the expression of tissue factor and thrombomodulin that occurs after stimulation, which is consistent with other studies [34] [35] [36] [37] . The observed Kd of 16 nM is at least two orders of magnitude higher than that for model membranes containing 20% phosphatidylserine [21, 22] , but is within the range observed for binding to platelets [38] Annexin V inhibits all the procoagulant complexes to the same extent. Before activation of the zymogens, a lag phase was observed, which was presumably necessary for functional complexes to be assembled. The lag time was not increased in the presence of rANV but the rate of zymogen activation was inhibited. This indicates that rANV inhibits the number of complexes formed. The IC50 value for all the complexes was about 40 nM, which is slightly higher than the Kd (about 16 nM). This could be due to differences in temperature, as the binding studies were performed at 4°C and the inhibition studies at 37 'C. The inhibition experiments were performed at 37 'C because the enzymes used exhibit optimal activity at this temperature. However, at 37 'C there is probably some uptake or degradation of annexin V which could be responsible for the slightly higher IC50.
In a number of previous studies, other cell surfaces have been used as the phospholipid surface to investigate the inhibitory potential of annexin V. With activated monocytes [40] , bovine endothelial cells [41] , fibroblasts and HL-60 cells [42] , IC50 values of 18 nM, < 20 nM, 150 nM and 15 nM respectively have been found, all of which are in the same range as found in the present study. In a recent paper, Ravanat et al. [23] found an IC50 of about 5,M for the TF/VII/X complex on PMA-stimulated endothelial cells, which is about 100 times higher than that found here with TNF-stimulated endothelial cells. In a control experiment, we therefore measured the inhibitory capacity of rANV on PMA-stimulated endothelial cells and found that the IC50 values was about ten times higher. In the same study, Ravanat et al. [23] also found that the TF/VII/X complex could be maximally inhibited by 80 %, which is consistent with the result found in the present study. To exclude the possibility that the residual activity found was the result of other clotting-factorbinding structures expressed on the surface as a result of activation of the cells, inhibition of the prothrombinase complex was compared in quiescent and stimulated cells. No differences were found in the maximal extent of activation and the IC50 value, and no residual activity was observed for all the other complexes. Another explanation for the 200 residual activity of the TF/VII/X complex might be that not only phospholipidbound factor X is activated by the TF/VII/X complex, but also factor X from the fluid phase. Activation of factor X which binds directly from the fluid phase to the tissue factor-factor VII complex will not be inhibited by rANV. Furthermore, this effect might also be the explanation for the differences in the IC50 values for the TF/VVII/X complex obtained with TNF-and PMA-stimulated HUVEC. Perhaps the tissue-factor concentration plays an important role in factor X activation from the fluid phase. At high tissue-factor concentrations, found in PMAstimulated HUVEC, there is more additional factor X activated from the fluid phase than in case of the lower tissue-factor concentration found on TNF-stimulated HUVEC.
Interference by endogenous annexin V (approx. 1 pg/cell) [19] on both measurements can be ignored. Suppose 100% of the endogenous annexin V is released during the experiments. This would result in an overestimation of the IC50 value by approx.
3.50 which is within the error of the experiment. Moreover, when the binding experiment was carried out without the EDTA washing step, the binding parameters did not change significantly with cultured endothelial cells (not shown).
In conclusion, rANV binds to the same extent to quiescent, PMA-and TNF-stimulated HUVEC, and, as a result of this binding, rANV is a potent inhibitor of blood coagulation mediated by endothelial cells.
